骨粗鬆症治療薬の世界市場2016-2026...市場調査レポートについてご紹介

【英文タイトル】Osteoporosis Global Market 2016-2026

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Overview of the Osteoporosis Industry and Market 2016-2026
1.2 Why You should Read this Report
1.3 How this Study Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Investigation for?
1.6 Method of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Associated Reports
1.9 About visiongain

2. Introduction to Osteoporosis
2.1 Osteoporosis Prevalence and Incidence in 2015
2.2 Osteoporosis: The Silent Killer
2.3 Osteoblasts are Critical in Bone Healing
2.4 Classifying Osteoporosis by Types
2.5 Classifying Osteoporosis by Treatments
2.5.1 Antiresorptive Medication
2.5.2 Anabolic Medication
2.6 Osteoporosis Risk Factors

3. Global Forecast for the Osteoporosis Market 2016-2026
3.1 The Global Osteoporosis Drug Market in 2015
3.2 The Global Osteoporosis Drug Market Forecast, 2016-2026
3.3 The Global Osteoporosis Market by Main Therapeutic Class, 2016-2026
3.3.1 The Antiresorptive Drug Submarket
3.3.1.1 Antiresorptive Drug Submarket Forecast 2016-2026
3.3.2 The Anabolic Drug Submarket
3.3.2.1 Anabolic Drug Submarket Forecast 2016-2026
3.3.3 The Others Submarket
3.3.3.1 The Others Submarket Forecast 2016-2026
3.4 Drivers and Restraints for the Global Osteoporosis Market 2016-2026

4. Individual Osteoporosis Drug Revenue Forecasts 2016-2026
4.1 The Bisphosphonates Submarket
4.1.1 The Bisphosphonates Revenue Forecast, 2016-2026
4.1.2 Merck (MSD)’s Fosamax (Alendronate)
4.1.2.1 Generic Competition for Fosamax in 2016
4.1.2.2 Fosamax Market Forecast 2016-2026
4.1.3 Roche’s Bonviva/Boniva (Ibandronate)
4.1.3.1 Boniva/Bonviva Market Forecast 2016-2026
4.1.4 Sanofi’s Actonel/Atelvia (Risedronate)
4.1.4.1 Actonel/Atelvia Market Forecast 2016-2026
4.1.5 Novartis’ Reclast/Aclasta (Zoledronate)
4.1.5.1 Reclast/Aclasta (Zoledronate) in the Leading National Markets, 2016
4.1.5.2 Generic Competition for Reclast/Aclasta (Zoledronate), 2016
4.1.5.3 Reclast/Aclasta (Zoledronate) Market Forecast 2016-2026
4.1.6 Ono Pharmaceutical’s/Astellas’ Recalbon/Bonoteo (Minodronate)
4.1.6.1 Recalbon/Bonoteo Market Forecast, 2016-2026
4.2 The SERMs Submarket
4.2.1 The SERMs Revenue Forecast, 2016-2026
4.2.2 Eli Lilly’s Evista (Raloxifene)
4.2.2.1 Generic Raloxifene Slashes Evista Profits
4.2.2.2 Evista Market Forecast 2016-2026
4.2.3 Pfizer’s Duavee
4.2.3.1 Duavee Market Forecast 2016-2026
4.3 The Global RANKL Antibody Market Forecast, 2016-2026
4.3.1 Amgen’s Prolia (Denosumab)
4.3.1.1 History of Prolia (Denosumab)
4.3.1.2 Prolia (Denosumab) Market Forecast 2016-2026
4.4 The Parathyroid Hormone Submarket
4.4.1 Parathyroid Hormone Submarket Forecast 2016-2026
4.4.2 Eli Lilly’s Forteo (Teriparatide)
4.4.3 Forteo Market Forecast 2016-2026
4.4.4 Preotact/Preos Withdrawn from the Market
4.5 The Others Submarket
4.5.1 The Others Submarket Forecast 2016-2026
4.5.2 Servier’s Protelos (Strontium Ranelate) 2016-2026
4.5.3 Protelos Market Forecast 2016-2026

5. Pipeline Drugs for the Osteoporosis Market 2016-2026
5.1 Merck (MSD)’s Odanacatib (MK 0822)
5.1.1 Odanacatib Market Forecast 2016-2026
5.2 Amgen’s Romosozumab (AMG 785)
5.2.1 Romosozumab Market Forecast 2016-2026
5.3 Blosozumab (LY2541546)
5.4 Radius Health’s Abaloparatide (BA-058)
5.4.1 Abaloparatide Market Forecast 2016-2026
5.5 ZP-PTH: Parathyroid
5.6 ZT-034: Will Need More Than Biomarkers for Approval

6. National Submarkets for the Osteoporosis Market 2016-2026
6.1 The Global Osteoporosis Market by Regional Breakdown, 2015, 2020 and 2026
6.2 The Global Osteoporosis Market Forecast by Regional Breakdown, 2015, 2020 and 2026
6.3 The US Osteoporosis Drug Market, 2015
6.3.1 The US Osteoporosis Market Forecast, 2016-2026
6.3.2 The Reimbursement System of the US
6.3.3 The US Must Improve Osteoporosis Preventation Measures
6.3.4 Drivers and Restraints for the US Osteoporosis Market, 2016-2026
6.4 The EU5 Osteoporosis Osteoporosis Market Forecasts, 2016-2026
6.4.1 The German Osteoporosis Market Forecast, 2016-2026
6.4.2 The French Osteoporosis Market Forecast, 2016-2026
6.4.3 The UK Osteoporosis Drug Market Forecast, 2016-2026
6.4.4 The Italian Osteoporosis Market Forecast, 2016-2026
6.4.5 The Spanish Osteoporosis Market Forecast, 2016-2026
6.5 The Japanese Osteoporosis Drug Market, 2015
6.5.1 The Japanese Osteoporosis Market Forecast, 2016-2026
6.5.2 Recent Trends in the Japanese Osteoporosis Market
6.6 The BRIC Countries Osteoporosis Market, 2015
6.6.1 The BRIC Countries Osteoporosis Market Forecast, 2016-2026
6.6.2 The Chinese Osteoporosis Market Forecast, 2016-2026
6.6.2.1 Drivers of Growth in the Chinese Market
6.6.3 The Indian Osteoporosis Market Forecast, 2016-2026
6.6.4 The Russian Osteoporosis Market Forecast, 2016-2026
6.6.5 The Brazilian Osteoporosis Market Forecast, 2016-2026
6.7 The South Korean Osteoporosis Market, 2016-2026
6.8 The Osteoporosis Market for the Rest of the World, 2016-2026
6.9 Additional Considerations for the National Osteoporosis Markets

7. Market Leaders for the Osteoporosis Market 2016-2026
7.1 Market Leaders in 2015
7.2 Eli Lilly
7.2.1 Eli Lilly Osteoporosis Drug Sales Forecast, 2016-2026
7.3 Amgen
7.3.1 Amgen: Reacquires All Rights for Prolia from GSK
7.3.2 Amgen Osteoporosis Drug Sales Forecast, 2016-2026
7.4 UCB
7.4.1 UCB Osteoporosis Drug Sales Forecast, 2016-2026
7.5 GSK
7.6 Merck and Co. (MSD)
7.6.1 Merck (MSD) Osteoporosis Drug Sales Forecast, 2016-2026
7.7 Allergan
7.8 Sanofi
7.9 Pfizer
7.10 Novartis
7.11 Radius Health

8. Qualitative Analysis of the Osteoporosis Market
8.1 SWOT (Strengths, Weaknesses, Opportunities and Threats) Analysis of the Osteoporosis Market, 2016-2026
8.2 STEP (Social, Technological, Economic and Political) Analysis of the Osteoporosis Market, 2016-2026

9. Research Interviews
9.1 Interview with Amy Porter, CEO and Executive Director of the National Osteoporosis Foundation (NOF), US and Clare Gill, Senior Director, Marketing, Consumer and Corporate Outreach at the NOF
9.1.1 On the Problem of Osteoporosis in Today’s Society
9.1.2 On the Work of the National Osteoporosis Foundation
9.1.3 On Drug Treatments and the Prevention of Osteoporosis
9.2 Interview with Paul Mitchell, Founder of Synthesis Medical Limited
9.2.1 On the Work of Synthesis Medical
9.2.2 On the Burden of Osteoporosis to Society
9.2.3 On Education and Policy for Osteoporosis
9.2.4 On Primary and Secondary Fractures
9.2.5 On Drug Treatments and Innovation for Osteoporosis
9.3 Interview with Cathy Yi, Orthopaedic Physical Therapy Clinical Specialist, Pursuit Physical Therapy
9.3.1 On the Therapy used at Pursuit Physical Therapy
9.3.2 On Primary and Secondary Fractures
9.3.3 On Education and Innovation for Osteoporosis

10. Conclusions
10.1 The Global Osteoporosis Market and Submarkets in 2015
10.2 The Global Osteoporosis Market and Submarkets until 2026
10.3 The National Markets for Osteoporosis in 2015
10.4 The National Markets for Osteoporosis until 2026
10.5 Leading Companies in the Osteoporosis Market
10.6 Drivers for the Osteoporosis Market
10.7 Challenges to Overcome for the Future Osteoporosis Drug Market

Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form


【レポート販売概要】

■ タイトル:骨粗鬆症治療薬の世界市場2016-2026
■ 英文:Osteoporosis Global Market 2016-2026
■ 発行日:2016年4月
■ 調査会社:visiongain
■ 商品コード:VGAIN6041540
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。